Skip to main content

Advertisement

Correction to: DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation

The original article was published in Journal of Experimental & Clinical Cancer Research 2019 38:474

Correction to: J Exp Clin Cancer Res (2019) 38:474

https://doi.org/10.1186/s13046-019-1442-2

In the original publication of this article [1], labelling within Fig. 7a was incorrect. The updated figure is shown below, with ‘DMT1’ now corrected to read ‘DNMT1’.

Fig. 7
figure1

IL-6 increases the expression of OCT4 through DNMT3b and IGF-1R activation in human HCC. a Model of how IL-6 increases theexpression of OCT4 through p-STAT3-DNMT3b-OCT4-DNMT1 activation in human HCC. b The combination use of nanaomycin and sorafenibsynergistically suppresses the cell proliferation of sorafenib resistant HCC cells

The authors sincerely apologize for the inconvenience caused to the readers.

Reference

  1. 1.

    Lai, et al. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation. J Exp Clin Cancer Res. 2019;38:474. https://doi.org/10.1186/s13046-019-1442-2.

Download references

Author information

Correspondence to Te-Sheng Chang or Yen-Hua Huang.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lai, S., Su, Y., Chi, C. et al. Correction to: DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation. J Exp Clin Cancer Res 39, 10 (2020). https://doi.org/10.1186/s13046-019-1518-z

Download citation